StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

Regenxbio price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Regenxbio's price to sales ratio was 2.6× on Nov 11, 2026, against 4.2× a year earlier. Over the last 5 years it ranged from 1.9× to 15.0×, with a median of 4.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.6×−1.9
2025Dec 31, 20254.5×−0.0
2024Dec 31, 20244.5×−3.4
2023Dec 29, 20237.9×+5.9
2022Dec 30, 20222.0×−13.0
2021Dec 31, 202115.0×+3.3
2020Dec 31, 202011.7×−11.8
2019Dec 31, 201923.5×+15.2
2018Dec 31, 20188.3×−94.6
2017Dec 29, 2017102.9×+36.0
2016Dec 30, 201667.0×−34.6
2015Dec 31, 2015101.6×–

More Regenxbio figures

See a number that looks wrong?